» Articles » PMID: 17317814

Nuclear Factor-kappaB in Development, Prevention, and Therapy of Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2007 Feb 24
PMID 17317814
Citations 143
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear factor-kappaB (NF-kappaB) is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in development of cancer. Major carcinogens and oncogenic viruses induce NF-kappaB activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-kappaB activation as an important common pathway in most forms of cancer. NF-kappaB target genes promote tumor cell proliferation, survival, migration, inflammation, and angiogenesis. Inhibition of NF-kappaB has been found to be an important mechanism of action of steroids, nonsteroidal anti-inflammatory drugs, and natural and synthetic compounds that show therapeutic and preventive activity. Newer agents targeting the proteasome, inhibitor-kappaB kinase, and other upstream kinases involved in NF-kappaB activation have shown anticancer activity in clinical or preclinical studies.

Citing Articles

SAR1A Induces Cell Growth and Epithelial-Mesenchymal Transition Through the PI3K/AKT/mTOR Pathway in Head and Neck Squamous Cell Carcinoma: An In Vitro and In Vivo Study.

Fang S, Wang J, Liu T, Jiang Y, Hua Q Biomedicines. 2024; 12(11).

PMID: 39595043 PMC: 11591717. DOI: 10.3390/biomedicines12112477.


The Effect of NF-κB Deactivation on Cancer Cell Response to ALA Mediated Photodynamic Therapy.

Al-Khafaji A, Salman M, Hassan H, Al-Shammari A Asian Pac J Cancer Prev. 2024; 25(6):2051-2058.

PMID: 38918667 PMC: 11382837. DOI: 10.31557/APJCP.2024.25.6.2051.


The role of lidocaine in cancer progression and patient survival.

Chida K, Kanazawa H, Kinoshita H, Roy A, Hakamada K, Takabe K Pharmacol Ther. 2024; 259:108654.

PMID: 38701900 PMC: 11162934. DOI: 10.1016/j.pharmthera.2024.108654.


Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.

Pakjoo M, Ahmadi S, Zahedi M, Jaafari N, Khademi R, Amini A Cell Commun Signal. 2024; 22(1):105.

PMID: 38331801 PMC: 10851565. DOI: 10.1186/s12964-023-01433-5.


Novel Insight into the Cellular and Molecular Signalling Pathways on Cancer Preventing Effects of : A Review.

Yasmin R, Gogoi S, Bora J, Chakraborty A, Dey S, Ghaziri G J Cancer Prev. 2023; 28(3):77-92.

PMID: 37830114 PMC: 10564632. DOI: 10.15430/JCP.2023.28.3.77.